Variable . | Estimated proportion of patients without MACE at 3 years . | Percentage mediation (95% CI) . | ||
---|---|---|---|---|
Liraglutide . | Liraglutide, adjusted for candidate mediator . | Placebo . | ||
HbA1c | 0.893 | 0.881 | 0.878 | 82.0 (11.7; 449.3) |
Body weight | 0.893 | 0.891 | 0.879 | 14.3 |
UACR | 0.892 | 0.888 | 0.880 | 33.3 |
Confirmed hypoglycemia | 0.893 | 0.892 | 0.878 | 6.7 |
SBP | 0.893 | 0.891 | 0.878 | 13.3 |
LDL cholesterol | 0.893 | 0.893 | 0.879 | 0.0 |
Insulin use | 0.892 | 0.890 | 0.878 | 14.3 |
SU use | 0.893 | 0.891 | 0.878 | 13.3 |
Variable . | Estimated proportion of patients without MACE at 3 years . | Percentage mediation (95% CI) . | ||
---|---|---|---|---|
Liraglutide . | Liraglutide, adjusted for candidate mediator . | Placebo . | ||
HbA1c | 0.893 | 0.881 | 0.878 | 82.0 (11.7; 449.3) |
Body weight | 0.893 | 0.891 | 0.879 | 14.3 |
UACR | 0.892 | 0.888 | 0.880 | 33.3 |
Confirmed hypoglycemia | 0.893 | 0.892 | 0.878 | 6.7 |
SBP | 0.893 | 0.891 | 0.878 | 13.3 |
LDL cholesterol | 0.893 | 0.893 | 0.879 | 0.0 |
Insulin use | 0.892 | 0.890 | 0.878 | 14.3 |
SU use | 0.893 | 0.891 | 0.878 | 13.3 |
SBP, systolic blood pressure; SU, sulfonylurea.